Comparative Pharmacology
Head-to-head clinical analysis: DISOPHROL versus FEXOFENADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPHROL versus FEXOFENADINE HYDROCHLORIDE.
DISOPHROL vs FEXOFENADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
Selective peripheral H1-receptor antagonist; inhibits histamine release from mast cells and basophils, reducing allergic symptoms without significant central nervous system penetration.
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
60 mg orally twice daily or 180 mg orally once daily; maximum 180 mg/day.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
14.4 hours in healthy adults; prolonged in renal impairment (up to 58 hours in end-stage renal disease) requiring dose adjustment.
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Primarily fecal (80%) with approximately 11% renal excretion of unchanged drug. Biliary excretion contributes to fecal elimination.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine